Annovis Bio (ANVS) Retained Earnings (2019 - 2026)
Annovis Bio (ANVS) posted Retained Earnings of -$181.3 million for Q1 2026, down 10.76% sequentially from -$163.7 million in Q4 2025, and down 29.14% YoY from -$255.9 million in Q1 2025.
Annovis Bio (ANVS) Retained Earnings (2019 - 2026) Analysis & Trends
Annovis Bio has reported Retained Earnings for 8 years, with the latest figure at -$181.3 million in Q1 2026.
- Quarterly Retained Earnings fell 29.14% year-over-year to -$181.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$181.3 million (down 29.14% YoY) and the FY2025 annual result came in at -$163.7 million, down 21.4% from the prior year.
- Retained Earnings slipped to -$181.3 million in Q1 2026 per ANVS's latest filing, from -$163.7 million in the prior quarter.
- Over five years, Retained Earnings peaked at $136.0 million in Q3 2024 and troughed at -$181.3 million in Q1 2026.
- A 5-year average of -$35.5 million and a median of -$63.8 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings jumped 539.6% in 2022, then plunged 231.55% in 2024.
- Over 5 years, Retained Earnings stood at -$54.1 million in 2022, then jumped by 289.64% to $102.5 million in 2023, then slumped by 231.55% to -$134.8 million in 2024, then retreated by 21.4% to -$163.7 million in 2025, then decreased by 10.76% to -$181.3 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$181.3 million, -$163.7 million, and -$153.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Annovis Bio | 66.78 Mn | 66.78 Mn | - | -196.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -181.31 Mn |
| Dec 31, 2025 | -163.70 Mn |
| Sep 30, 2025 | -153.87 Mn |
| Jun 30, 2025 | -146.61 Mn |
| Mar 31, 2025 | -140.40 Mn |
| Dec 31, 2024 | -134.85 Mn |
| Sep 30, 2024 | 136.05 Mn |
| Jun 30, 2024 | -116.35 Mn |
| Mar 31, 2024 | -111.30 Mn |
| Dec 31, 2023 | 102.51 Mn |
| Sep 30, 2023 | 94.70 Mn |
| Jun 30, 2023 | 94.07 Mn |
| Mar 31, 2023 | -63.79 Mn |
| Dec 31, 2022 | -54.05 Mn |
| Sep 30, 2022 | 80.92 Mn |
| Jun 30, 2022 | 78.56 Mn |
| Mar 31, 2022 | 76.66 Mn |
| Dec 31, 2021 | -28.73 Mn |
| Sep 30, 2021 | -22.81 Mn |
| Jun 30, 2021 | 68.57 Mn |